FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308444858> ?p ?o ?g. }

• W4308444858 endingPage "1869" @default.
• W4308444858 startingPage "1869" @default.
• W4308444858 abstract "Objective: A comparative analysis was performed to investigate the potential risk factors of Adverse Events Following Immunization (AEFI) after receiving different booster vaccines. Methods: From 18 January 2021 to 21 January 2022, the Health Care Workers (HCWs) of Guizhou Provincial Staff Hospital (Guizhou Province, China) who received a third Booster vaccine, that was either homologous (i.e., (i) a total of three doses of Vero cell vaccine or (ii) three doses of CHO cell vaccine) or (iii) heterologous with two first doses of Vero cell vaccine, being either CHO cell vaccine or adenovirus type-5 (Ad5) vectored COVID-19 vaccine, were asked to complete a self-report questionnaire form to provide information on any AEFI that may have occurred in the first 3 days after vaccination with the booster. The frequency of AEFI corresponding to the three different booster vaccines was compared, and the risk factors for predicting AEFI were determined by multivariate logistic regression analysis. Results: Of the 904 HCWs who completed the survey, 792 met the inclusion criteria. The rates of AEFI were 9.8% (62/635) in the homologous Vero cell booster group, 17.3% (13/75) in the homologous CHO cell booster group, and 20.7% (17/82) in the heterologous mixed vaccines booster group, and the rates were significantly different (χ2 = 11.5, p = 0.004) between the three groups of vaccines. Multivariate logistic regression analysis showed that: (1) compared to the homologous Vero cell booster group, the risk of AEFI was about 2.1 times higher (OR = 2.095, 95% CI: 1.056–4.157, p = 0.034) in the CHO cell booster group and 2.5 times higher (OR = 2.476, 95% CI: 1.352–4.533, p = 0.003) in the mixed vaccines group; (2) the odds for women experiencing AEFI were about 2.8 times higher (OR = 2.792, 95% CI: 1.407–5.543, p = 0.003) than men; and (3) compared to the non-frontline HCWs, the risk of AEFI was about 2.6 times higher (OR = 2.648, 95% CI: 1.473–4.760, p = 0.001) in the doctors. Conclusion: The AEFI in all three booster groups are acceptable, and serious adverse events are rare. The risk of AEFI was higher in doctors, which may be related to the high stress during the COVID-19 epidemic. Support from government and non-governmental agencies is important for ensuring the physical and mental health of HCWs." @default.
• W4308444858 created "2022-11-11" @default.
• W4308444858 creator A5008273613 @default.
• W4308444858 creator A5008998082 @default.
• W4308444858 creator A5013302343 @default.
• W4308444858 creator A5023250695 @default.
• W4308444858 creator A5025898938 @default.
• W4308444858 creator A5029153523 @default.
• W4308444858 creator A5040647242 @default.
• W4308444858 creator A5059920698 @default.
• W4308444858 creator A5060165452 @default.
• W4308444858 creator A5079722676 @default.
• W4308444858 date "2022-11-04" @default.
• W4308444858 modified "2023-10-14" @default.
• W4308444858 title "Investigation of Adverse Events Experienced by Healthcare Workers following Immunization with Homologous or Heterologous COVID-19 Booster Vaccinations" @default.
• W4308444858 cites W1565460446 @default.
• W4308444858 cites W1967431794 @default.
• W4308444858 cites W1995002349 @default.
• W4308444858 cites W2063102691 @default.
• W4308444858 cites W2125110865 @default.
• W4308444858 cites W2169556962 @default.
• W4308444858 cites W2556202573 @default.
• W4308444858 cites W3012832369 @default.
• W4308444858 cites W3025400426 @default.
• W4308444858 cites W3041485345 @default.
• W4308444858 cites W3042383115 @default.
• W4308444858 cites W3045505453 @default.
• W4308444858 cites W3092766467 @default.
• W4308444858 cites W3115737775 @default.
• W4308444858 cites W3120079690 @default.
• W4308444858 cites W3158373340 @default.
• W4308444858 cites W3162487576 @default.
• W4308444858 cites W3163361643 @default.
• W4308444858 cites W3170840401 @default.
• W4308444858 cites W3178778712 @default.
• W4308444858 cites W3189762432 @default.
• W4308444858 cites W3192739702 @default.
• W4308444858 cites W3193938173 @default.
• W4308444858 cites W3198390285 @default.
• W4308444858 cites W3200674187 @default.
• W4308444858 cites W3206891011 @default.
• W4308444858 cites W3207092933 @default.
• W4308444858 cites W4200049649 @default.
• W4308444858 cites W4200133104 @default.
• W4308444858 cites W4200148964 @default.
• W4308444858 cites W4200192318 @default.
• W4308444858 cites W4205405695 @default.
• W4308444858 cites W4206675538 @default.
• W4308444858 cites W4210450230 @default.
• W4308444858 cites W4213435273 @default.
• W4308444858 cites W4220763712 @default.
• W4308444858 cites W4226248511 @default.
• W4308444858 cites W4226343533 @default.
• W4308444858 cites W4228999274 @default.
• W4308444858 cites W4238883756 @default.
• W4308444858 cites W4295094759 @default.
• W4308444858 doi "https://doi.org/10.3390/vaccines10111869" @default.
• W4308444858 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36366377" @default.
• W4308444858 hasPublicationYear "2022" @default.
• W4308444858 type Work @default.
• W4308444858 citedByCount "0" @default.
• W4308444858 crossrefType "journal-article" @default.
• W4308444858 hasAuthorship W4308444858A5008273613 @default.
• W4308444858 hasAuthorship W4308444858A5008998082 @default.
• W4308444858 hasAuthorship W4308444858A5013302343 @default.
• W4308444858 hasAuthorship W4308444858A5023250695 @default.
• W4308444858 hasAuthorship W4308444858A5025898938 @default.
• W4308444858 hasAuthorship W4308444858A5029153523 @default.
• W4308444858 hasAuthorship W4308444858A5040647242 @default.
• W4308444858 hasAuthorship W4308444858A5059920698 @default.
• W4308444858 hasAuthorship W4308444858A5060165452 @default.
• W4308444858 hasAuthorship W4308444858A5079722676 @default.
• W4308444858 hasBestOaLocation W43084448581 @default.
• W4308444858 hasConcept C104317684 @default.
• W4308444858 hasConcept C121332964 @default.
• W4308444858 hasConcept C12590561 @default.
• W4308444858 hasConcept C126322002 @default.
• W4308444858 hasConcept C1276947 @default.
• W4308444858 hasConcept C151956035 @default.
• W4308444858 hasConcept C159047783 @default.
• W4308444858 hasConcept C187212893 @default.
• W4308444858 hasConcept C197934379 @default.
• W4308444858 hasConcept C203014093 @default.
• W4308444858 hasConcept C203165030 @default.
• W4308444858 hasConcept C22070199 @default.
• W4308444858 hasConcept C2522874641 @default.
• W4308444858 hasConcept C2780115692 @default.
• W4308444858 hasConcept C2780801004 @default.
• W4308444858 hasConcept C54355233 @default.
• W4308444858 hasConcept C71924100 @default.
• W4308444858 hasConcept C86803240 @default.
• W4308444858 hasConcept C8891405 @default.
• W4308444858 hasConcept C89138240 @default.
• W4308444858 hasConceptScore W4308444858C104317684 @default.
• W4308444858 hasConceptScore W4308444858C121332964 @default.
• W4308444858 hasConceptScore W4308444858C12590561 @default.
• W4308444858 hasConceptScore W4308444858C126322002 @default.
• W4308444858 hasConceptScore W4308444858C1276947 @default.

• next